Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect?

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Metastatic renal cell cancer (RCC) presents significant treatment challenges.
• Sunitinib, a tyrosine kinase receptor inhibitor (TKRI), is a standard treatment for advanced RCC.
• Radiotherapy is an option for palliation and local control in metastatic RCC.

Observation:

• A patient with metastatic RCC received hypofractionated radiotherapy (8 Gy x 2 doses) to a rib metastasis.
• The patient was concurrently treated with sunitinib.
• The metastatic mass showed a nearly complete clinical disappearance post-treatment.

Findings:

• Concurrent administration of hypofractionated radiotherapy and sunitinib resulted in significant tumor regression.
• This case suggests a potential synergistic effect between TKRIs and radiotherapy in managing metastatic RCC.
• The observed response highlights the efficacy of novel treatment combinations.

Implications:

• This case supports further investigation into combined TKRI and radiotherapy strategies for metastatic RCC.
• Understanding the synergy between targeted therapy and radiation could optimize treatment protocols.
• Hypofractionated radiotherapy may be a viable option in combination regimens for advanced cancers.